Literature DB >> 29567722

Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?

Tiziana Masini1, Janika Hauser2, Rutendo Kuwana3, Nguyen Nhat Linh4, Ernesto Jaramillo4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29567722     DOI： 10.1183/13993003.02480-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  3 in total

1.  Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study.

Authors:  C A Rodriguez; M B Brooks; L Guglielmetti; C Hewison; M F Jachym; E Lessem; F Varaine; C D Mitnick
Journal:  Public Health Action       Date:  2019-03-21

2.  Linking market authorizations of medicines with disease burden in South Africa.

Authors:  K Narsai; H G M Leufkens; A K Mantel-Teeuwisse
Journal:  J Pharm Policy Pract       Date:  2021-04-01

3.  Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.

Authors:  Ken Kurosawa; Stefaan Rossenu; Jeike Biewenga; Sivi Ouwerkerk-Mahadevan; Wouter Willems; Etienne Ernault; Chrispin Kambili
Journal:  J Clin Pharmacol       Date:  2021-06-12       Impact factor: 3.126
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.